Skin & hair

Getting a Second Opinion on a Skin Biopsy

Save

Pathologists disagree most on melanocytic lesions, where the line between an atypical mole and an early melanoma is a genuine spectrum. A second read can confirm the diagnosis or revise details — like a melanoma's measured depth — that change the surgery. Here is when a re-read is worth it, how to have your slides sent, and what it costs.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Should you get a second opinion on a skin biopsy?

A second opinion on a skin biopsy is most worth it when the diagnosis is a melanocytic (mole-type) lesion, when the report is borderline or uses words like atypical or in situ, or when the result will lead to major surgery, a serious label, or a big change in your life. Asking for one is routine and expected — cancer centers re-read outside slides as a matter of course before they treat — and it is not an insult to the first pathologist. A pathology report is not a single objective fact so much as an expert's interpretation, and interpretations of hard cases can honestly differ.

You do not need a second opinion for every biopsy. A clearly benign result on an ordinary spot, or a common diagnosis that matches how the lesion looked and behaved, usually does not warrant one. The value of a re-read rises with the stakes of being wrong and with the difficulty of the call. The two questions to ask are: how consequential is this diagnosis, and how hard is this kind of specimen to read? When both answers are high, a second read earns its place. A second opinion is a routine quality check, most valuable for mole-type lesions and any diagnosis that will drive surgery.

Why pathologists disagree — especially about moles

Pathologists disagree more often on melanocytic lesions than on almost anything else in skin, because the line between a benign atypical mole and an early melanoma is a genuine spectrum rather than a bright line. The diagnosis of melanoma rests on histopathologic interpretation of the tissue under the microscope 1, and for borderline lesions two expert dermatopathologists can read the same slide and reach different conclusions. That is not incompetence; it is the nature of the specimen.

The clinical features that raise suspicion in the first place — the ABCDE signs of asymmetry, irregular borders, varied color, larger diameter, and evolution 2 — are what prompt a biopsy, but they do not settle the diagnosis. Only the tissue does, and reading that tissue is a specialized skill. A dermatopathologist is a pathologist with extra training specifically in skin, and having one read or re-read a difficult melanocytic slide is exactly the kind of expertise a second opinion buys. This is why a melanoma second opinion, in particular, is so often recommended even by the first physician.

A second read can confirm the original diagnosis, downgrade it, or upgrade it. Confirmation is the most common outcome and is itself valuable: it lets you proceed with confidence. But because the direction can go either way, a re-read is best understood as reducing uncertainty, not as a search for a better answer.

For the hardest melanocytic cases, pathologists sometimes describe the diagnosis in tiers of certainty rather than a single flat label, and may add a note suggesting complete removal or an outside review. That hedging is not indecision — it is an honest signal that the specimen sits in the gray zone where a second, subspecialty read adds the most. When your report itself invites a second look, that is the strongest possible reason to arrange one.

How to actually request a second opinion

Requesting a second opinion is a concrete, patient-driven process, and the material you need already exists. Your diagnosis lives on glass slides, and in the paraffin blocks the tissue is stored in, and you have the right to have that material sent to another pathologist or institution for review. You are not re-doing the biopsy; you are having the same tissue re-read by a different, often more specialized, eye.

The practical steps are straightforward: - Ask for your pathology report first. Get a copy and note the specimen number, the diagnosis, and the name of the lab. - Choose where the re-read happens. Academic medical centers, and especially National Cancer Institute–designated cancer centers, run formal second-review services and re-read outside slides routinely before treatment. - Request that the slides or blocks be sent. The original lab releases the physical material to the reviewing pathologist; your treating clinician or the second institution can order this, usually with a signed release from you. - Mind the timing. For a possible melanoma, a second read is most useful before the definitive surgery, because the re-read can change what that surgery should be.

Keep your own copies of everything — the reports, and the fact that slides exist and where they are — because you may need to direct the material more than once. Understanding what happens during a skin biopsy and how the specimen is handled makes these requests easier to make; the people who move slides between labs do this every week.

When a second read changes the plan

A second read changes management most often by changing the tumor's measured depth or its borderline classification, and in melanoma those measurements drive everything downstream. Staging depends heavily on the Breslow thickness — how deep the melanoma extends — and on whether the surface is ulcerated 3. If a re-read revises the thickness, it can change the recommended surgical margin and whether a sentinel lymph node biopsy is offered 4.

The biopsy technique itself feeds this. For a suspected melanoma, a narrow full-thickness sample that removes the whole lesion is preferred over a superficial shave or a partial punch, precisely because a partial sample can under-measure depth and blur staging 5. When the original biopsy was partial, a second opinion sometimes recommends re-excision to get an accurate measurement rather than simply re-reading what is there.

None of this means the first diagnosis was wrong. It means the first diagnosis is the input to decisions — margins, node sampling, follow-up intervals — where a small change in the read can mean a meaningfully different operation. Getting that input right before the definitive procedure is the whole reason the timing matters. Early, accurate diagnosis is also what underlies the strong survival difference between melanoma caught thin and melanoma caught late 6.

When a re-read does differ from the original, the two reports are reconciled by your treating team rather than one simply overriding the other, and sometimes a third expert is asked to break the tie. The practical rule is that the more consequential the decision the diagnosis triggers, the more worthwhile it is to be certain of the diagnosis before acting on it — which is why the re-read belongs before the operation, not after.

What a second opinion costs and whether insurance covers it

A pathology second opinion is usually billed as a consultation on the existing slides, and when it is medically necessary — which a possible cancer diagnosis is — it is often covered, though coverage and your share vary by plan. The charge is generally far smaller than the treatment that follows it, and it is money spent to make sure that treatment is the right one. As with any pathology, ask for the cost in advance.

Be aware that pathology is billed separately from the office visit, which is why a biopsy can generate more than one bill and sometimes a surprise pathology bill weeks later. A second-opinion review adds its own professional fee, so it helps to ask three questions up front: whether the reviewing pathologist is in your network, what the consultation will cost if they are not, and what the billing code will be so you can check it against your plan. If you are paying cash, ask for the self-pay price directly. If the review comes back the same, that agreement is documented in your record and can settle lingering doubt; if it differs, your team reconciles the two reports before deciding.

Cost should not be the reason a high-stakes diagnosis goes unconfirmed. If a formal second read is out of reach, it is worth asking whether your own treating institution has a dermatopathologist who can review the case internally, which is often included in the care you are already receiving.

Getting it right the first time

The best way to avoid needing a re-do is a well-chosen first biopsy, and for a lesion that might be melanoma that means sampling the whole thing at full thickness when feasible. Guidelines favor an excisional or narrow-margin biopsy that captures the entire depth of a suspicious melanocytic lesion over a superficial shave, so the pathologist can measure how deep it goes and stage it accurately 1. When anatomy or size makes complete removal impractical, a representative full-thickness sample of the most abnormal area is the fallback 5.

This is where the choice between a shave biopsy versus a punch biopsy matters, and it is a reasonable thing to discuss before the procedure. A broad shave (saucerization) can work for many lesions, while a punch or an excision may be better for a deeper or clearly pigmented one. The point is not that one technique is always right, but that for a possible melanoma the technique should preserve the ability to stage.

When the first biopsy was ideal, a second opinion becomes a clean re-read of good material. When it was partial, the second opinion may sensibly recommend getting better material. Either way, knowing how the specimen was taken tells you how much a re-read can and cannot resolve.

Two different second opinions: the slide and the plan

There are actually two second opinions you can seek, and they answer different questions. A pathology second opinion re-reads the tissue: is the diagnosis correct? A clinical second opinion re-reads the plan: given this diagnosis, is the recommended treatment the right one? Both are legitimate, and for a serious skin cancer many people get both — first confirming the slide, then discussing the surgery or therapy with a second specialist.

The broader principle of a cancer second opinion is well established: for a diagnosis that will shape months of treatment, a fresh expert look is a normal part of good care, not a detour. If you pursue one, bring the pathology report, the slides or a note that they can be sent, your imaging if any, and the proposed treatment plan. A second opinion works best when the reviewer has the same material the first one did. Ask directly whether your case was or can be reviewed by a dermatopathologist, since that subspecialty read is often what a second opinion is really about.

The throughline is uncertainty reduction. You are not looking for someone to disagree; you are making sure a diagnosis carrying real consequences has been checked with the care those consequences deserve.

Common questions

No. Re-reading slides is a routine quality step, and cancer centers do it automatically on outside cases before they treat. Good clinicians expect it for difficult or high-stakes diagnoses and will help arrange it. You are not questioning anyone's competence; you are confirming a call that will shape your treatment, which is exactly what a second opinion is for.

Ask the original lab or your treating clinician to release the glass slides or the tissue blocks to the reviewing pathologist or institution, usually with a signed release from you. You are not re-doing the biopsy — the same tissue is simply re-read. Academic and cancer-center pathology departments handle these transfers routinely.

Melanocytic lesions — moles and anything possibly melanoma — top the list, because the line between a benign atypical mole and an early melanoma is genuinely hard and readers can differ. Reports that use words like atypical, borderline, or in situ, and any diagnosis that will lead to major surgery, are also strong reasons to have the slide re-read.

It might. A re-read can confirm the diagnosis, or it can revise details like a melanoma's measured depth that determine the surgical margin and whether a sentinel node is sampled. Most re-reads confirm the original, which is itself useful. When they differ, your team reconciles the reports before deciding, ideally before the definitive surgery.

Often, when it is medically necessary — and a possible cancer diagnosis generally qualifies — though your share depends on your plan and whether the reviewing pathologist is in network. The consultation fee is usually small next to the treatment it informs. Ask for the cost and the billing code in advance, and request the self-pay price if you are paying cash.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a skin diagnosis needs a faster look

  • A mole or spot that is rapidly growing, changing color, bleeding, or crusting while you wait on results or a review
  • A biopsy report of melanoma or another skin cancer with no follow-up appointment scheduled
  • A new firm lump under the skin near the biopsy site, or a swollen lymph node

This article explains how and when to seek a second opinion on a skin biopsy and is general information, not medical advice. Decisions about your diagnosis and treatment should be made with the clinicians caring for you.

References

  1. 1.Swetter SM, Tsao H, Bichakjian CK, et al. (2019). Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2018.08.055Melanoma diagnosis rests on histopathologic interpretation, and the guideline-preferred biopsy is an excisional or narrow-margin full-thickness sample to preserve staging.
  2. 2.Tsao H, Olazagasti JM, Cordoro KM, et al. (2015). Early detection of melanoma: reviewing the ABCDEs. Journal of the American Academy of Dermatology. PMID 25698455The ABCDE features are clinical criteria that prompt evaluation of a mole for melanoma but do not settle the pathologic diagnosis.
  3. 3.Gershenwald JE, Scolyer RA, Hess KR, et al. (2017). Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. doi:10.3322/caac.21409Melanoma staging depends on tumor thickness (Breslow) and ulceration among the key evidence-based staging factors.
  4. 4.National Cancer Institute (PDQ Adult Treatment Editorial Board) (2025). Melanoma Treatment (PDQ®)–Health Professional Version. NIH / National Cancer Institute. linkSurgical excision margins and sentinel lymph node biopsy are treatment decisions that follow from the tumor's diagnosis and depth.
  5. 5.American Family Physician (2011). Shave and Punch Biopsy for Skin Lesions. American Family Physician. linkFor a suspected melanoma, a narrow full-thickness (excisional/saucerization) biopsy is preferred over a superficial shave or partial punch to preserve staging accuracy.
  6. 6.National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (2025). Cancer Stat Facts: Melanoma of the Skin. NIH / National Cancer Institute (SEER). linkMelanoma five-year relative survival differs markedly by stage at diagnosis, underscoring the value of accurate early staging.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy